A BILL 
To amend title XIX of the Social Security Act to provide 
for a State option under the State Medicaid plan to 
provide DNA sequencing clinical services for certain chil-
dren, provide for a study by the National Academy of 
Medicine on the use of genetic and genomic testing to 
improve health care, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Advancing Access to 
4
Precision Medicine Act’’. 
5
01:39 Sep 21, 2019
H4393
2 
•HR 4393 IH
SEC. 2. STATE OPTION TO PROVIDE DNA SEQUENCING 
1
CLINICAL SERVICES FOR CERTAIN CHIL-
2
DREN. 
3
Title XIX of the Social Security Act (42 U.S.C. 1396 
4
et seq.) is amended by adding at the end the following 
5
new section: 
6
‘‘SEC. 1947. STATE OPTION TO PROVIDE DNA SEQUENCING 
7
CLINICAL SERVICES FOR CERTAIN CHIL-
8
DREN. 
9
‘‘(a) 
IN
GENERAL.—Notwithstanding 
section 
10
1902(a)(1) 
(relating 
to 
statewideness), 
section 
11
1902(a)(10)(B) (relating to comparability), and any other 
12
provision of this title for which the Secretary determines 
13
it is necessary to waive in order to implement this section, 
14
beginning on the first day of the first fiscal quarter that 
15
begins on or after the date of the enactment of this sec-
16
tion, a State, at its option as a State plan amendment, 
17
may provide for medical assistance under this title to an 
18
eligible individual for purposes of providing the individual 
19
with DNA sequencing clinical services. 
20
‘‘(b) PAYMENTS.— 
21
‘‘(1) IN
GENERAL.—A State shall provide a 
22
health care provider (as defined by the State) with 
23
payments for the provision of DNA sequencing clin-
24
ical services to any eligible individual. Payments 
25
made to a health care provider for such services 
26
01:39 Sep 21, 2019
H4393
3 
•HR 4393 IH
shall be treated as medical assistance for purposes 
1
of section 1903(a), except that, during the first 8 
2
fiscal year quarters that the State plan amendment 
3
is in effect, the Federal medical assistance percent-
4
age applicable to such payments shall be equal to 75 
5
percent. 
6
‘‘(2) METHODOLOGY.—The State shall specify 
7
in the State plan amendment the methodology the 
8
State will use for determining payment for the provi-
9
sion of DNA sequencing clinical services. Such meth-
10
odology for determining payment shall be established 
11
consistent with section 1902(a)(30)(A). 
12
‘‘(3) PLANNING GRANTS.— 
13
‘‘(A) IN GENERAL.—Beginning on the date 
14
described in subsection (a), the Secretary may 
15
award planning grants to States for purposes of 
16
developing a State plan amendment under this 
17
section. A planning grant awarded to a State 
18
under this paragraph shall remain available 
19
until expended. 
20
‘‘(B) STATE
CONTRIBUTION.—A State 
21
awarded a planning grant shall contribute an 
22
amount equal to the State percentage deter-
23
mined under section 1905(b) for each fiscal 
24
year for which the grant is awarded. 
25
01:39 Sep 21, 2019
H4393
4 
•HR 4393 IH
‘‘(c) HOSPITAL REFERRALS.—A State shall include 
1
in the State plan amendment a requirement for any hos-
2
pital that is a participating provider under the State plan 
3
(or a waiver of such plan) to establish procedures for re-
4
ferring any eligible individual who seeks or needs treat-
5
ment in a hospital emergency department to a health care 
6
provider who is qualified (as determined by the State) to 
7
provide DNA sequencing clinical services. 
8
‘‘(d) REPORTS BY STATES.—Not later than three 
9
years after the date on which the State plan amendment 
10
under this section is approved, a State shall submit a re-
11
port to the Administrator of the Centers for Medicare & 
12
Medicaid Services and the Administrator of the Health 
13
Resources and Services Administration on— 
14
‘‘(1) the extent to which DNA sequencing clin-
15
ical services reduce health disparities; and 
16
‘‘(2) the extent to which coverage under the 
17
State plan (or a waiver of such plan) impedes the 
18
use of genetic and genomic testing that may improve 
19
clinical outcomes for eligible individuals enrolled in 
20
the State plan (or under a waiver of such plan). 
21
‘‘(e) REPORTS BY HEALTH CARE PROVIDERS.—As a 
22
condition for receiving payment for DNA sequencing clin-
23
ical services provided to an eligible individual, a health 
24
care provider shall report to the State, in accordance with 
25
01:39 Sep 21, 2019
H4393
5 
•HR 4393 IH
such requirements as the Secretary shall specify, on all 
1
applicable measures for determining the quality of such 
2
services. 
3
‘‘(f) DEFINITIONS.—In this section: 
4
‘‘(1) ELIGIBLE INDIVIDUAL.—The term ‘eligible 
5
individual’ means an individual who— 
6
‘‘(A) is eligible for medical assistance 
7
under the State plan (or a waiver of such plan); 
8
‘‘(B) is under the age of 21 (or, at the op-
9
tion of the State, under the age of 20, 19, or 
10
18 as the State may choose), or in the case of 
11
an 
individual 
described 
in 
section 
12
1902(a)(10)(A)(i)(IX), under the age of 26; 
13
‘‘(C) has been referred or admitted to a 
14
pediatric intensive care unit for a chronic or 
15
undiagnosed disease; 
16
‘‘(D) has been seen by at least one medical 
17
specialist for such chronic or undiagnosed dis-
18
ease; and 
19
‘‘(E) is suspected by at least one medical 
20
specialist to have a pediatric-onset genetic dis-
21
ease. 
22
‘‘(2) DNA SEQUENCING CLINICAL SERVICES.— 
23
The term ‘DNA sequencing clinical services’, with 
24
respect to an eligible individual— 
25
01:39 Sep 21, 2019
H4393
6 
•HR 4393 IH
‘‘(A) means a determination of an exact 
1
sequence of deoxyribonucleic acid bases in the 
2
genome of such individual, and, if for the sole 
3
benefit of the individual, a biological parent of 
4
such individual for the purpose of determining 
5
whether one or more potentially disease-causing 
6
genetic variants are present in the genome of 
7
such individual or such biological parent; and 
8
‘‘(B) includes— 
9
‘‘(i) sequencing of the entire genome, 
10
of the exome, of a panel of genes, or other 
11
regions of the genome; and 
12
‘‘(ii) any analysis, interpretation, and 
13
data report derived from such sequenc-
14
ing.’’. 
15
SEC. 3. NATIONAL ACADEMY OF MEDICINE STUDY. 
16
(a) IN GENERAL.—Not later than 4 years after the 
17
date of the enactment of this Act, the Secretary of Health 
18
and Human Services shall enter into an arrangement with 
19
the National Academy of Medicine under which the Acad-
20
emy agrees to study— 
21
(1) how genetic and genomic testing may im-
22
prove preventative care and precision medicine; 
23
(2) how genetic and genomic testing may re-
24
duce health disparities; 
25
01:39 Sep 21, 2019
H4393
7 
•HR 4393 IH
(3) how the Federal Government may help to 
1
reduce barriers to genetic and genomic testing, in-
2
cluding— 
3
(A) encouraging the expansion of health 
4
insurance coverage of genetic and genomic test-
5
ing, including diagnostic, predictive, and pre-
6
symptomatic testing, and DNA sequencing clin-
7
ical services (as defined in section 1947 of the 
8
Social Security Act (as added by section 2)); 
9
(B) supporting the collection of evidence 
10
for the clinical utility and appropriate use of ge-
11
netic and genomic tests; and 
12
(C) improving access to genetic counselors, 
13
pathologists, and other relevant professions, in-
14
cluding strengthening related workforce edu-
15
cation and training efforts; 
16
(4)(A) the extent to which coverage provisions 
17
in the Medicare and Medicaid programs under titles 
18
XVIII and XIX of the Social Security Act (42 
19
U.S.C. 1395 et seq., 1396 et seq.) may restrain the 
20
use of genetic and genomic testing that may improve 
21
clinical outcomes for beneficiaries; 
22
(B) the extent to which coverage provided pur-
23
suant to section 1947 of the Social Security Act (as 
24
added by section 2) increased the use of genetic and 
25
01:39 Sep 21, 2019
H4393
8 
•HR 4393 IH
genomic testing and improved clinical outcomes for 
1
beneficiaries; and 
2
(C) how the Centers for Medicare & Medicaid 
3
Services may make coverage determinations that 
4
better suit a precision medicine approach to treat-
5
ment; and 
6
(5) how genetic and genomic testing may im-
7
prove health outcomes for all populations in the 
8
United States, including— 
9
(A) individuals with a rare disease, includ-
10
ing— 
11
(i) a metabolic disease; 
12
(ii) a hereditary cancer syndrome; and 
13
(iii) a neurologic disease with known 
14
treatments; and 
15
(B) special populations, including— 
16
(i) infants and children; 
17
(ii) critically ill (non-infectious and 
18
non-trauma) patients; 
19
(iii) transplant patients; 
20
(iv) individuals with cardiac disease; 
21
and 
22
(v) individuals with, or who have a 
23
family history of, a birth defect or develop-
24
mental disability. 
25
01:39 Sep 21, 2019
H4393
9 
•HR 4393 IH
(b) REPORT.— 
1
(1) IN GENERAL.—The arrangement under sub-
2
section (a) shall provide for the National Academy 
3
of Medicine to submit, not later than 6 years after 
4
the date of enactment of this Act, a report on the 
5
results of the study under subsection (a) to— 
6
(A) the Secretary of Health and Human 
7
Services; 
8
(B) the Committee on Ways and Means 
9
and the Committee on Energy and Commerce 
10
of the House of Representatives; and 
11
(C) the Committee on Finance and the 
12
Committee on Health, Education, Labor, and 
13
Pensions of the Senate. 
14
(2) CONSULTATION.—The arrangement under 
15
subsection (a) shall provide for the National Acad-
16
emy of Medicine, in developing the report required 
17
by paragraph (1), to consult with physicians, other 
18
health professionals, health educators, health profes-
19
sional organizations, relevant companies, patients, 
20
patient organizations, the Health Resources and 
21
Services Administration, the National Cancer Insti-
22
tute, the National Institutes of Health, the Agency 
23
for Healthcare Research and Quality, and the Cen-
24
ters for Medicare & Medicaid Services. 
25
01:39 Sep 21, 2019
H4393
10 
•HR 4393 IH
(3) USE
OF
INFORMATION.—The National 
1
Academy of Medicine shall, to the extent possible, in 
2
conducting the study under subsection (a), utilize in-
3
formation included in the reports submitted pursu-
4
ant to subsections (d) and (e) of section 1947 of the 
5
Social Security Act (as added by section 2). 
6
Æ 
01:39 Sep 21, 2019
H4393
